CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...
Among people with low levels of LDL cholesterol—even those who achieve very large absolute reductions with statin therapy—higher levels of lipoprotein(a) are associated with an increased risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback